C0023951||locus coeruleus
C0948482||analgesic efficacy
C0067685||N-acetylaspartylglutamate peptidase
C0067685||glutamate carboxypeptidase II
C0014432||inhibitors
C1451894||ZJ43
C0910831||2-PMPA
C0130693||N-acetylaspartylglutamate
C0130693||N-acetylaspartylglutamate
C0027908||neurotransmitter
C0024660||mammalian
C0027763||nervous system
C0130693||N-acetylaspartylglutamate
C0532371||group II metabotropic glutamate receptor
C0532371||mGluR3
C0067685||extracellular enzyme, glutamate carboxypeptidase II
C0067685||glutamate carboxypeptidase II
C1515655||in vivo
C0014432||Inhibitors of this enzyme
C0002771||analgesic
C0599779||animal models
C0234251||inflammatory
C3714625||neuropathic
C0279530||bone cancer
C0030193||pain
C0130693||N-acetylaspartylglutamate
C0067685||glutamate carboxypeptidase II
C0023951||locus coeruleus
C0949307||formalin
C2985236||footpad
C0012644||model
C0014432||GCPII inhibitors
C0234251||inflammatory pain
C0521329||spinal
C0028351||noradrenaline
C0948482||analgesic efficacy
C0021485||injection
C0532371||group II mGluR
C1254351||antagonist
C0021896||intrathecal (spinal) injection
C0304513||alpha 2 adrenergic receptor antagonist
C0025991||microinjection
C1254351||α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist
C0441988||contralateral
C0023951||locus coeruleus
C2985236||Footpad
C0021368||inflammation
C0017789||glutamate
C0441988||contralateral
C0023951||locus coeruleu
C0014432||GCPII inhibitor
C0021485||injection
C0014432||GCPII inhibitors
C0441988||contralateral
C0441989||ipsilatera
C0023951||locus coeruleus
C0234251||inflammatory pain
C0441988||contralateral
C0021896||intrathecal injection
C0304513||alpha 2 adrenergic receptor antagonist
C0948482||analgesic efficacy
C0014432||GCPII inhibitors
C0441988||contralatera
C0023951||locus coeruleus
C0532371||group II mGluR
C1528634||α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid
C0001639||alpha 2 adrenergic receptors